CLL Cello Health Plc

TIDMCLL

RNS Number : 5327N

Cello Health PLC

09 May 2018

FOR IMMEDIATE RELEASE 9 May 2018

Cello Health plc

Result of AGM

At the Annual General Meeting of Cello Health plc (AIM:CLL) held today, all the resolutions put to shareholders were duly passed.

Enquiries:

 
  Cello Health plc                   020 7812 8460 
  Mark Scott, Chief Executive 
  Mark Bentley, Group Finance 
   Director 
  Cenkos Securities plc 
  Mark Connelly/Harry Hargreaves     020 7397 8900 
 
  Buchanan 
   Mark Court                        020 7466 5000 
  Jamie Hooper 
  Sophie Wills 
 
 

About Cello Health plc

We are a global healthcare-focused advisory Group comprised of a set of leading clinical, commercial advisory and digital delivery capabilities. We currently service 24 of the top 25 pharmaceutical clients globally as well as a wide range of biotech, diagnostics, devices and other key non-healthcare clients.

We enable clients to differentiate their propositions and drive brand success in ever more complex global markets. We deliver our services through nearly 1,000 highly skilled professionals utilising latest thinking, technology and digital solutions.

Cello Health plc delivers its services from an office network in the UK, USA, and Asia, with hub offices in New York, Philadelphia, London, Edinburgh, Farnham and Cheltenham.

For further information, please visit: https://cellohealthplc.com/

This information is provided by RNS

The company news service from the London Stock Exchange

END

RAGEAASNEFAPEFF

(END) Dow Jones Newswires

May 09, 2018 08:14 ET (12:14 GMT)

Cello Health (LSE:CLL)
Historical Stock Chart
From Apr 2024 to May 2024

Cello Health (LSE:CLL)
Historical Stock Chart
From May 2023 to May 2024